Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 
ANACOR PHARMACEUTICALS, INC.
(Name of Issuer)

Common Stock, $0.001 Par Value
(Title of Class of Securities)

032420 101
(CUSIP Number)

Victoria A. Whyte
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
Telephone: +44 (0)208 047 5000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 14, 2012
(Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  o

Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
 
 
 
 
 
 CUSIP No.   032420 101
 
  SCHEDULE 13D/A  Page 2 of 7
 
1
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
GlaxoSmithKline plc
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 
                                                                                                                            (a) o
                                                                                                                            (b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS
WC
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON
WITH
7
SOLE VOTING POWER
2,771,374
8
SHARED VOTING POWER
-0-
9
SOLE DISPOSITIVE POWER
2,771,374
10
SHARED DISPOSITIVE POWER
-0-
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,771,374 shares of Common Stock (1)
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES        o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.8% of the shares of Common Stock (2)
14
TYPE OF REPORTING PERSON
CO
 

Footnotes:
 
(1)           Shares held of record by GlaxoSmithKline LLC f/k/a SmithKline Beecham Corporation, a wholly owned subsidiary of the Reporting Person, issued as of November 30, 2010.
 
(2)           Based on 35,568,645 shares of Common Stock as of November 30, 2012.
 

 
 
 
 
 CUSIP No.   032420 101
 
  SCHEDULE 13D/A  Page 3 of 7
 
 
This Amendment No. 1 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on December 10, 2010 (the “Original Schedule 13D”) with respect to the shares of common stock, par value $0.001 per share (the “Common Stock”), of Anacor Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).  Unless otherwise indicated, each capitalized term used but not defined herein shall have the meaning assigned to such term in the Original Schedule 13D.
 
Item 2.           Identity and Background.
 
The response set forth in Item 2 of the Original Schedule 13D is hereby amended by deleting Schedule 1 in its entirety, and replacing it with Schedule 1 attached hereto.
 
Item 5.           Interest in Securities of the Issuer.
 
The response set forth in the first paragraph of Item 5 of the Original Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:
 
                       (a) GlaxoSmithKline plc beneficially owns 2,771,374 shares of Common Stock, issued as of November 30, 2010, which represents 7.8% of the 35,568,645 shares of Common Stock outstanding as of November 30, 2012.  The Issuer issued an additional 3,250,000 shares of Common Stock on February 14, 2012 and 4,000,000 shares of Common Stock on October 23, 2012.
 
 
 
 
 
 
 
 
 
 
 CUSIP No.   032420 101
 
  SCHEDULE 13D/A  Page 4 of 7
 
SIGNATURE
 
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
 
 
  GLAXOSMITHKLINE PLC
   
  /s/ Victoria A. Whyte              
  By: Victoria A. Whyte
  Title: Company Secretary

 

 
 
 
 
 
 CUSIP No.   032420 101
 
  SCHEDULE 13D/A  Page 5 of 7
 
 SCHEDULE I

Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
             
Board of Directors
            
             
Sir Andrew Witty
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Executive Officer
  
British
             
Simon Dingemans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Financial Officer
  
British
             
Dr. Moncef Slaoui
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director
Chairman Global Research & Development and Vaccines
  
Moroccan, Belgian & US
             
Sir Christopher Gent
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chairman and Company Director
  
British
             
Professor Sir Roy Anderson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Dr. Stephanie Burns
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Stacey Cartwright
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Sir Crispin Davis
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Judy Lewent
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
 
             
Sir Deryck Maughan
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
 
 
 
 
 
 CUSIP No.   032420 101
 
  SCHEDULE 13D/A  Page 6 of 7
 

Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
 
Dr. Daniel Podolsky
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Tom de Swaan
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
Dutch
             
Sir Robert Wilson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
British
             
Lynn Elsenhans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Jing Ulrich
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Company Director
  
US
             
Hans Wijers*
   980 Great West Road
Brentford
Middlesex, England
TW8 9GS
   Company Director   Dutch
         
*Appointment with effect from 1 April 2013        
             
             
Corporate Executive Team
            
             
Sir Andrew Witty
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Executive Officer
  
British
             
Simon Dingemans
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director and Chief Financial Officer
  
British
             
Dr. Moncef Slaoui
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Executive Director
Chairman Global Research & Development and Vaccines
  
Moroccan, Belgian & US
             
Simon Bicknell
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Senior Vice President, Governance, Ethics and Assurance
  
British
             
Deirdre Connelly
  
1600 Vine Street,
Philadelphia, PA
19102
  
President, North America
Pharmaceuticals
  
US
 
 
 
 
 
 
 
 
 CUSIP No.   032420 101
 
  SCHEDULE 13D/A  Page 7 of 7
 

Name
  
Business Address
  
Principal Occupation or Employment
  
Citizenship
 
Marc Dunoyer
 
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Head of Rare Diseases Unit and Chairman of GlaxoSmithKline Japan
  
French
             
Abbas Hussain
  
150 Beach Road
22-00 Gateway West
189720
Singapore
  
President, Europe & Emerging Markets & Asia Pacific
 
  
British
             
William Louv
  
Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709
  
Senior Vice President, Core Business Services & Chief Information Officer
  
US
             
David Redfern
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Chief Strategy Officer
  
British
             
Christophe Weber
  
Avenue Fleming, 20
B-1300 Wavre
Belgium
  
President, Vaccines
  
French
             
Claire Thomas
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Senior Vice President,
Human Resources
  
British
             
Philip Thomson
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
Senior Vice President, Global Communications
  
British
             
Daniel Troy
  
One Franklin Plaza
Philadelphia, PA
19102
  
Senior Vice President & General Counsel
  
US
             
Dr. Patrick Vallance
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
President, Pharmaceuticals R&D
  
British
             
Emma Walmsley
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
President, Consumer Healthcare Worldwide
  
British
             
Roger Connor
  
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
  
President, Global Manufacturing & Supply
  
British